When Antidepressants Stop Working: A Gilbert Guide to Treatment-Resistant Depression
Standard antidepressants do not work for everyone. When a patient tries two or more medications at adequate doses without meaningful improvement, that pattern has a clinical name: treatment-resistant depression. At Core Self in Gilbert, we work specifically with patients at that point and offer two evidence-based treatments designed for exactly this situation.
What Treatment-Resistant Depression Actually Is
Treatment-resistant depression, or TRD, is defined clinically as a major depressive episode that has not responded adequately to at least two antidepressant medications at therapeutic doses, taken for a sufficient duration. That distinction matters because it separates patients who may need a different medication from patients who need a fundamentally different kind of treatment.
TRD is more common than most patients expect. A significant portion of people diagnosed with major depressive disorder find that standard antidepressants provide limited, temporary, or no relief. The experience of cycling through medications, each one carrying weeks of waiting and side effects, without arriving at consistent relief is exhausting in a way that is difficult to describe. TRD is not a character flaw and it is not evidence that depression is untreatable. It is clinical information about the mechanism driving the depression.
Why Some Depression Resists Standard Treatment
Most first-line antidepressants work by increasing the availability of serotonin, norepinephrine, or both. These are called SSRIs, or selective serotonin reuptake inhibitors, and SNRIs, or serotonin-norepinephrine reuptake inhibitors. For many patients, this approach is effective. For others, the biology of their depression involves systems these medications do not directly address (National Institutes of Health).
Research has increasingly focused on the glutamate system, the brain's primary excitatory neurotransmitter network, as a pathway involved in depression that serotonin-targeted medications do not reach. The recognition of this gap opened the door to rapid-acting treatments that work through different mechanisms and have demonstrated results in patients for whom standard medications have failed (National Institute of Mental Health, 2024).
Other factors can also contribute to treatment resistance. Genetic variation in how individuals metabolize medications means some patients are processing standard doses too quickly or too slowly to reach a therapeutic effect. Underlying medical issues, including thyroid dysfunction, vitamin deficiencies, and chronic inflammation, can sustain depressive symptoms independently of medication. Our evaluation process at Core Self examines all of these factors before any treatment recommendation is made.
TMS Therapy for Treatment-Resistant Depression
TMS therapy, or transcranial magnetic stimulation, is a non-invasive procedure that uses targeted magnetic pulses to stimulate areas of the brain associated with mood regulation. It requires no medication, no anesthesia, and no downtime. Patients drive themselves to and from every session and return to their regular routine immediately afterward.
At Core Self, TMS therapy involves daily sessions five days a week for four to six weeks. Before treatment begins, we conduct an initial brain mapping session to precisely identify the treatment target. Each session runs between 20 and 40 minutes. TMS is FDA-cleared for major depressive disorder and is covered by most major insurance plans, including Medicare and Tricare, for patients who meet clinical criteria. Our team handles prior authorization and insurance verification before treatment begins so there are no financial surprises.
TMS may help reduce depressive symptoms in patients who have not responded adequately to antidepressants. Results vary by individual, and a thorough clinical evaluation before treatment begins helps identify patients for whom TMS is most appropriate.
SPRAVATO® for Treatment-Resistant Depression
SPRAVATO® is an FDA-approved nasal spray containing esketamine, a form of ketamine developed specifically for clinical use in depression treatment. The U.S. Food and Drug Administration approved SPRAVATO® as the first medication of its kind for treatment-resistant depression, and it subsequently received approval as the first and only monotherapy for adults with treatment-resistant depression (U.S. Food and Drug Administration) (Johnson & Johnson).
SPRAVATO® is available at Core Self for adults with treatment-resistant depression and for adults with major depressive disorder with suicidal thoughts or actions. It must be used alongside an oral antidepressant and is self-administered under direct clinical supervision in our office. Patients remain on-site for a monitoring period of approximately two hours after each dose, and will need a trusted person to drive them home. The induction phase involves one to two sessions per week during the first several weeks, followed by a maintenance schedule adjusted to the patient's individual response and goals.
SPRAVATO® is covered by most major insurance plans. Our team verifies coverage and handles prior authorization before treatment begins.
If you have tried multiple antidepressants and found only limited relief, you may also find it helpful to read about how TRD is understood at a broader level in our earlier post, When Depression Doesn't Get Better: Understanding Treatment-Resistant Depression.
The Evaluation Process at Core Self
Before recommending TMS or SPRAVATO® for any patient, we conduct a thorough psychiatric evaluation. This includes reviewing your full history of prior antidepressant trials, assessing for medical conditions that may be contributing to your symptoms, and in some cases recommending pharmacogenomic testing to determine whether genetic factors affected how prior medications worked for you.
We also screen for bipolar spectrum features, which can affect antidepressant response and may require a different treatment approach. The evaluation exists because we want to understand why the depression has been resistant before recommending what to try next.
Cost is a real factor in accessing advanced care, and we want to address it directly. TMS is covered by most major insurance plans, as is SPRAVATO®. For patients uncertain about their coverage, our team verifies benefits before any treatment begins. Financing options are available. The first step is a free consultation, which you can schedule by calling or contacting us at (520) 346-0831 or booking online.
We understand that patients who have been through multiple treatment failures may arrive with exhaustion and skepticism. That history is valid, and it is also information we take seriously in the evaluation. We encourage every patient to discuss their options openly with their provider and explore what the next step might look like before drawing any conclusions. Results vary by individual.
Frequently Asked Questions
How do I know if I qualify as treatment-resistant?
The general clinical threshold is two or more antidepressant trials at adequate doses for adequate duration without sufficient improvement. If you are unsure whether your prior trials meet that standard, our evaluation process will clarify it. Some patients who have been told they are treatment-resistant have not actually completed full therapeutic trials. For others, the pattern is clearly documented in their history.
What is the difference between TMS and SPRAVATO®?
TMS is a non-invasive procedure that uses magnetic pulses applied externally to stimulate specific brain regions. SPRAVATO® is an FDA-approved nasal spray containing esketamine, which acts at glutamate receptors in the brain. Both are available at Core Self for treatment-resistant depression. Which is the right fit depends on clinical factors, patient history, insurance coverage, and your own preferences, all of which your provider will discuss with you during the evaluation.
Will I need to stop my current antidepressant to try TMS or SPRAVATO®?
Not necessarily. Some patients continue existing medications alongside TMS. SPRAVATO® is specifically approved for use in combination with an oral antidepressant. Decisions about your current medications are made collaboratively with your provider based on your individual history and response.
How long does it take to see results?
TMS response typically develops over the course of the four-to-six-week treatment series. Some patients notice changes within the first few weeks; others see the most significant response toward the end of the course or after it concludes. SPRAVATO® can produce improvement more rapidly for some patients, sometimes within hours or days of the first sessions. Individual response varies for both treatments, and results vary by individual.
What if I have tried other advanced treatments before and they did not work?
That history is part of what we review during the evaluation. The range of available options for TRD has expanded, and most patients who come to us have not exhausted all of them. An evaluation at Core Self starts with your full treatment history and works forward from there.
Key Takeaways
Treatment-resistant depression is defined as a major depressive episode that has not responded adequately to two or more antidepressant medications at therapeutic doses.
Standard antidepressants primarily target serotonin and norepinephrine. TRD often involves the glutamate system and other pathways those medications do not directly reach.
Core Self offers TMS therapy and SPRAVATO® for eligible patients with TRD, both of which work through mechanisms distinct from conventional antidepressants.
A thorough evaluation reviewing your full treatment history is the required starting point before any advanced treatment is recommended at Core Self.
Results vary by individual. TMS and SPRAVATO® are covered by most major insurance plans. Our team verifies coverage before treatment begins.
Conclusion
If your depression has not responded to antidepressants, that history is information, not a final answer. At Core Self in Gilbert, we review that history carefully, evaluate what may have contributed to the treatment resistance, and discuss the options that may be appropriate for your specific situation. Call us at (520) 346-0831 or book a free consultation online to take the next step.
References
National Institutes of Health. Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review. https://pmc.ncbi.nlm.nih.gov/articles/PMC8395812/
National Institute of Mental Health. New Hope for Rapid-Acting Depression Treatment (2024). https://www.nimh.nih.gov/news/science-updates/2024/new-hope-for-rapid-acting-depression-treatment
U.S. Food and Drug Administration. FDA Approves New Nasal Spray Medication for Treatment-Resistant Depression. https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified
Johnson & Johnson. SPRAVATO® Approved in the U.S. as the First and Only Monotherapy for Adults With Treatment-Resistant Depression. https://www.jnj.com/media-center/press-releases/spravato-esketamine-approved-in-the-u-s-as-the-first-and-only-monotherapy-for-adults-with-treatment-resistant-depression
Medical Disclaimer: The information in this blog is for educational purposes only and does not constitute medical advice. TMS therapy and SPRAVATO® are available at Core Self for patients who meet clinical criteria following a thorough psychiatric evaluation. Individual results vary. Neither TMS nor SPRAVATO® is appropriate for every patient, and treatment decisions should only be made under the supervision of a qualified psychiatric provider familiar with your full medical and mental health history. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room.
